Qingruitan®Brivaracetam Tablets
Brivaracetam is an innovative third-generation antiepileptic drug that selectively targets synaptic vesicle protein 2A (SV2A) with high affinity.
Fudingning® Zonisamide Tablets
Zonisamide (ZNS), also known as zonisamide, is a new antiepileptic drug. Since its launch in Japan in 1989, it has been used for over 30 years and has treated more than a million patients worldwide. Due to its unique chemical structure and broad-spectrum, potent antiepileptic effects, it is effective for both focal and generalized epilepsy, as well as epilepsy syndromes.
Xinkang® Lacosamide Oral Solution
Xinkang® Lacosamide Oral Solution is another new member of Qingfeng Pharmaceutical's antiepileptic drug family, following the launch of lacosamide tablets and injection.
Xinkang® Lacosamide Injection
Xinkang® Lacosamide Injection is the first third-generation novel antiepileptic injection in China and is the only drug that highly selectively targets the slow-inactivated sodium ion channels.
Xinkang® Lacosamide Tablets
Xinkang® Lacosamide Tablets are the first third-generation novel antiepileptic drug in China, approved for market in January 2019. It is now available in over 58 countries including the U.S., EU, Japan, and China, and has been used by over 500,000 epilepsy patients globally.
Langkang® Perampanel Tablets
Langkang® Perampanel Tablets are a third-generation antiepileptic drug (ASM) that non-competitively binds to the AMPA glutamate receptor on postsynaptic neurons.
Xinkun® Sodium Valproate Concentrated Solution for Injection
Xinkun® Sodium Valproate Concentrated Solution for Injection is a classic broad-spectrum anti-epileptic drug.
Qingruike® Pregabalin Oral Solution
Qingruike® Pregabalin Oral Solution contains pregabalin, a calcium channel modulator that targets the α2-δ subunit of voltage-gated calcium channels. Besides relieving pain, it also improves sleep and mood.